
1. clin exp ophthalmol. 2016 dec;44(9):824-837. doi: 10.1111/ceo.12785. epub 2016
jul 26.

herpes simplex virus keratitis: update pathogenesis current
treatment oral topical antiviral agents.

tsatsos m(1)(2)(3)(4), macgregor c(2), athanasiadis i(3), moschos mm(4), hossain 
p(2), anderson d(2).

author information: 
(1)royal eye infirmary, dorset county hospital nhs foundation trust, dorchester, 
uk.
(2)southampton university hospitals nhs foundation trust, southampton, uk.
(3)moorfields eye hospital nhs foundation trust, london, uk.
(4)university athens, athens, greece.

comment in
    clin exp ophthalmol. 2017 apr;45(3):316-317.
    clin exp ophthalmol. 2017 dec;45(9):932.

ophthalmic herpes simplex viral keratitis responsible range ocular
manifestations superficial epithelial disease stromal keratitis and
endotheliitis. herpetic eye disease study guided management of
herpetic eye disease almost twenty years, newer medications as
valacyclovir available considered better bioavailability 
than acyclovir. review, examine existing evidence the
pathogenesis different ophthalmic herpes simplex viral keratitis disease
modalities role oral topically administered antiviral drugs the
treatment herpes simplex viral keratitis.

Â© 2016 royal australian new zealand college ophthalmologists.

doi: 10.1111/ceo.12785 
pmid: 27273328  [indexed medline]

